Science Corporation

$230M Series C for first vision-restoring BCI

Science Corporation — Science closed an oversubscribed $230M Series C (total ~$490M) to commercialize PRIMA — a retinal BCI that restored form vision in dry-AMD patients (NEJM-published). A European launch later this year would make it the first BCI vision product on the market.

B Brain-Computer Interfaces Science Corporation